A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) (NCT06878261)
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
🩺 Plain-English Summary (8th-Grade Level)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Who can join: Review the eligibility criteria below.
Location: Research Site — Cullman, Alabama
Age range: 40 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (268 Sites)
Showing the first 25 of 268 sites.
- Research Site — Cullman, Alabama
- Research Site — Phoenix, Arizona
- Research Site — Scottsdale, Arizona
- Research Site — Inglewood, California
- Research Site — Los Angeles, California
- Research Site — Palo Alto, California
- Research Site — Redding, California
- Research Site — San Diego, California
- Research Site — New Britain, Connecticut
- Research Site — Wilmington, Delaware
- Research Site — Bay Pines, Florida
- Research Site — Boynton Beach, Florida
- Research Site — Clearwater, Florida
- Research Site — Fleming Island, Florida
- Research Site — Jacksonville, Florida
- Research Site — Leesburg, Florida
- Research Site — Margate, Florida
- Research Site — Miami, Florida
- Research Site — Miami, Florida
- Research Site — Miami Lakes, Florida
- Research Site — Ocala, Florida
- Research Site — Palmetto Bay, Florida
- Research Site — Winter Park, Florida
- Research Site — Adairsville, Georgia
- Research Site — Atlanta, Georgia
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Obstructive Pulmonary Disease (COPD)
- Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke — Pleasanton, California
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Birmingham, Alabama
- WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor). — Baltimore, Maryland
- Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations — Durham, North Carolina
- Multi-Center Clean Air Randomized Controlled Trial in COPD — Birmingham, Alabama
- To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment — Phoenix, Arizona
Explore by condition: All Chronic Obstructive Pulmonary Disease (COPD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.